SCCS Preliminary Opinion on Sodium Bromothymol Blue (C186) as hair dyeing
Ingredients: SODIUM BROMOTHYMOL BLUE (C186)

Date of publication: 28/10/2022

Following the request from the EU Commission for a scientific opinion on the hair dye Sodium Bromothymol Blue (C186), on October 2022 the Scientific Committee on Consumer Safety (SCCS) issued a preliminary opinion. In light of the data provided, when used in non-oxidative hair colouring products up to a maximum on-head concentration of 0.5%, the SCCS is of the opinion that the complete safety of Sodium Bromothymol Blue could not be assessed.

BACKGROUND

Sodium Bromothymol Blue (C186) (C27H27Br2NaO5S, CAS number: 34722-90-2) is a weak acid. The degree of ionisation depends on the pKa and the pH of the solution resulting in two possible forms and different colours. The cyclic nonionised form is mostly present at pH < pKa (7.1). At pH 7.1, 50% of each form is present in solution. As the pH increases, the open ionised form is mostly present, at pH > pKa. Sodium Bromothymol Blue is used as cosmetic ingredient in hair dyeing, non-oxidative hair colouring products with a final on-head concentration of up to 0.5%.

Following the request from the EU Commission for a scientific opinion on the hair dye Sodium Bromothymol Blue (C186), on October 2022 the Scientific Committee on Consumer Safety (SCCS) issued a preliminary opinion which public consultation period ends on 23rd December 2022.

WHAT’S NEW?

In light of the data provided, when used in non-oxidative hair colouring products up to a maximum on-head concentration of 0.5%, the SCCS is of the opinion that the complete safety of Sodium Bromothymol Blue could not be assessed because: 

  • A Toxicological Threshold of Concern (TTC) approach was used to assess the safety of three impurities present in Sodium Bromothymol Blue. However, the SCCS estimated the Systemic Exposure Dose (SED) to exceed the TTC threshold for Cramer class III for non-genotoxic substances. At the same time, the use of TTC on its own to justify the safety of substances that are regulated under the EU Cosmetic Regulation is not sufficient to waive the information requirements on essential toxicological endpoints. 

Regarding the scientific concerns of the use of Sodium Bromothymol Blue in cosmetic products, the SCCS concluded that: 

  • While the use of TTC is acceptable to justify the safety of impurities and cosmetic ingredients that are added to a final product at low concentrations, it is not acceptable for the substances that are regulated under the EU Cosmetic Regulation. For this, data from New Approach Methodologies (NAMs) that are scientifically-accepted for the purpose, and/or other acceptable in vivo data on systemic toxicity, are required in an overall weight of evidence for safety. 

Even though the Applicant has provided data on two batches of Sodium Bromothymol Blue, the SCCS has concerns about the impurities identified in one of the batches (Guanghua batch), as the levels of these impurities exceed the TTC threshold both individually and collectively. Therefore, the SCCS considers that the presence of these impurities is not safe, and a batch of Sodium Bromothymol Blue matching the impurity profile of Guanghua batch cannot be recommended for use in marketed products.

References: 

1. Scientific Committee on Consumer Safety (SCCS) – Opinion on Sodium Bromothymol Blue (C186) (CAS No. 34722-90-2), preliminary version of 24-25 October 2022, SCCS/1645/22 

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »